Vigil Neuroscience, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sionna Gets CF Compounds AbbVie License

The executives we surveyed on the clinical trial landscape identified several sweeping trends that are expected to drive change over the coming year. As in so many spheres, data, digital technology an

Eisai Co., Ltd. has a challenging task ahead in bringing its Biogen, Inc. -partnered amyloid protofibril-clearing antibody Leqembi (lecanemab) to Alzheimer’s patients in a market that is struggling

To say that 2022 has gotten off to a rough start for investors that back biopharmaceutical companies would be an understatement. The Nasdaq Biotechnology Index (NBI) is down 14.3% year-to-date and the